BTIG Maintains Buy on GeneDx Hldgs, Raises Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Mark Massaro maintains a Buy rating on GeneDx Holdings (NASDAQ:WGS) and raises the price target from $15 to $19.
April 30, 2024 | 11:44 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GeneDx Holdings' Buy rating is maintained by BTIG, with the price target increased from $15 to $19.
The upgrade in the price target by a reputable analyst like Mark Massaro suggests a strong confidence in GeneDx Holdings' future performance. This is likely to positively influence investor sentiment and potentially increase the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100